Switch theme
Sign up to access all valuation multiples
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
2000
40
LTM Revenue $4.9M
LTM EBITDA -$3.9M
$239M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oryzon Genomics has a last 12-month revenue (LTM) of $4.9M and a last 12-month EBITDA of -$3.9M.
In the most recent fiscal year, Oryzon Genomics achieved revenue of n/a and an EBITDA of -$4.6M.
Oryzon Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oryzon Genomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.7M | XXX | $15.7M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.9M | XXX | -$4.6M | XXX | XXX | XXX |
| EBITDA Margin | -79% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$3.0M | XXX | -$5.1M | XXX | XXX | XXX |
| EBIT Margin | -61% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.2M | XXX | -$3.8M | XXX | XXX | XXX |
| Net Margin | -86% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oryzon Genomics's stock price is EUR 3 (or $3).
Oryzon Genomics has current market cap of EUR 209M (or $235M), and EV of EUR 212M (or $239M).
See Oryzon Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $239M | $235M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oryzon Genomics has market cap of $235M and EV of $239M.
Oryzon Genomics's trades at n/a EV/Revenue multiple, and -52.4x EV/EBITDA.
Equity research analysts estimate Oryzon Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oryzon Genomics has a P/E ratio of -55.7x.
See valuation multiples for Oryzon Genomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $235M | XXX | $235M | XXX | XXX | XXX |
| EV (current) | $239M | XXX | $239M | XXX | XXX | XXX |
| EV/Revenue | 48.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -61.5x | XXX | -52.4x | XXX | XXX | XXX |
| EV/EBIT | -79.1x | XXX | -46.7x | XXX | XXX | XXX |
| EV/Gross Profit | 50.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -55.7x | XXX | -62.4x | XXX | XXX | XXX |
| EV/FCF | 138.2x | XXX | -14.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOryzon Genomics's last 12 month revenue growth is 152%
Oryzon Genomics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Oryzon Genomics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oryzon Genomics's rule of X is 301% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oryzon Genomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 152% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -79% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 301% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oryzon Genomics acquired XXX companies to date.
Last acquisition by Oryzon Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Oryzon Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oryzon Genomics founded? | Oryzon Genomics was founded in 2000. |
| Where is Oryzon Genomics headquartered? | Oryzon Genomics is headquartered in Spain. |
| How many employees does Oryzon Genomics have? | As of today, Oryzon Genomics has 40 employees. |
| Is Oryzon Genomics publicy listed? | Yes, Oryzon Genomics is a public company listed on MAD. |
| What is the stock symbol of Oryzon Genomics? | Oryzon Genomics trades under ORY ticker. |
| When did Oryzon Genomics go public? | Oryzon Genomics went public in 2015. |
| Who are competitors of Oryzon Genomics? | Similar companies to Oryzon Genomics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oryzon Genomics? | Oryzon Genomics's current market cap is $235M |
| What is the current revenue of Oryzon Genomics? | Oryzon Genomics's last 12 months revenue is $4.9M. |
| What is the current revenue growth of Oryzon Genomics? | Oryzon Genomics revenue growth (NTM/LTM) is 152%. |
| What is the current EV/Revenue multiple of Oryzon Genomics? | Current revenue multiple of Oryzon Genomics is 48.5x. |
| Is Oryzon Genomics profitable? | Yes, Oryzon Genomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oryzon Genomics? | Oryzon Genomics's last 12 months EBITDA is -$3.9M. |
| What is Oryzon Genomics's EBITDA margin? | Oryzon Genomics's last 12 months EBITDA margin is -79%. |
| What is the current EV/EBITDA multiple of Oryzon Genomics? | Current EBITDA multiple of Oryzon Genomics is -61.5x. |
| What is the current FCF of Oryzon Genomics? | Oryzon Genomics's last 12 months FCF is $1.7M. |
| What is Oryzon Genomics's FCF margin? | Oryzon Genomics's last 12 months FCF margin is 35%. |
| What is the current EV/FCF multiple of Oryzon Genomics? | Current FCF multiple of Oryzon Genomics is 138.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
